Can This Be The Answer To HIV? Authorities From China To Approve The 1st Ever Long-Acting Cure For HIV
A number of people have been reported to be looking forward as China's national drug authority has announced that the examined clinical research results on a domestically produced anti-HIV drug is in its final phase prior to officially approving the drug.
Is This 'Injection' Finally The Answer To HIV?
According to Global Times, it was found that once the drug named as Albuvirtide has already been approved, experts perceive it as the world's first long-acting injection for HIV treatment. Developed by the Nanjing-based Frontier Biotechnologies Inc, the medicine is known to have the ability to block fusion of the viral and host cell membranes, which in turn, disrupts the HIV life cycle in its earliest stage.
The wonder drug has allegedly been put into phase-3 clinical trials in 12 clinical centers across the country since February 2014. However, authorities have explained that different from traditional oral drugs that require daily use, Albuvirtide is an injection solution that can be administered weekly.
In one of his statements reported by ECNS, Zhao Yan, a treatment specialist at the National Center for AIDS and Sexually Transmitted Disease Control and Prevention, has revealed that currently, almost seven or eight oral drugs for AIDS are currently provided to patients for free. She further explains that if it could be included in the country's health insurance system, the drug, in a form of injection solution can actually be considered as an alternative to patients
On the other hand, experts have revealed that the current cocktail therapy widely used in HIV treatments can only bring the HIV virus under temporary control but cannot cure the disease. As of the present time, it was found that a number of long-acting AIDS drug are in development across the globe. However, none of them has reportedly been approved for sale. Experts have highly emphasized that only Albuvirtide and a few in the United States have entered phase three of clinical trials.
OnePlus 5 Revealed In TV Ad, Flagship Killer Reaches 300,000 Online Registrations
A surprise TV ad shown in India revealed what the OnePlus 5 looks like while over in China, more than 300,000 have already registered for the flagship killer.
Apple's iPhone Is No Longer China's Favorite
Apple is experiencing serious competition in Greater China from homegrown brands.
Robot Wars: China's MegaBot Challenger Wants To Fight In World's First Robot Battle
China may join in the upcoming robot wars, challenging giant fighting robots made by USA and Japan. Dubbed the Monkey King, the latest megabot challenger may kick off a robot fighting league.
Leaked OnePlus 5 Photo Samples Could Confirm This Cool Upgrade
OnePlus 5 made headlines this week as samples of its camera photos were leaked. Experts who analyzed the leaked photos think that a cool new upgrade might be in the works.
Xiaomi Mi 6 Might Not Launch In US And Europe Until 2019
This delay might be because of the "innovation for everyone" mantra that Xiang and Donovan Sung, Xiaomi’s director of product management, have been harping on.
Illegal Flying Stones Of 4 Drones Cause Grounded Flights & Thousands Of Stranded Passengers
Flying model airplanes and unmanned aerial vehicles are banned 10km (6 miles) away from the centerline of the runways, and 20km from the end of runways at civil airports, according to local government organizations.
MORE IN ITECHPOST
'Tokyo Ghoul' Season 3 Delayed By Its Live-Action Movie? Ken Kenaki Returns With Another Identity?
"Tokyo Ghoul" season 3's release is delayed and there are countless speculations as to why it is being pushed back. Reports claim that the show is to give way to "One Punch Man" and "My Hero Acdemia" but new rumors say that it's lack of materials and storyline as well as its live-action movie are causing the delay.